good news Biomerica Announces New Patent for
the Technology it is Using to Develop
Tests for Ulcers and Stomach Cancer
NEWPORT BEACH, Calif., Aug. 11 /PRNewswire/ -- Biomerica, Inc. (Nasdaq: BMRA - news)
announced today that the U.S. Patent Office has issued a new patent for the technology it is licensing
to develop an exclusive new generation of tests for detecting highly virulent strains of Helicobacter
pylori bacteria. The virulent strains of this bacterium cause peptic ulcers and can lead to stomach
cancer if untreated.
The patent describes a method for detecting antibodies against the CagA protein expressed only by
virulent strains of H. pylori. Unlike other H. pylori tests, this second-generation test will pinpoint
individuals who have strains of the bacterium that can cause the greatest damage in the body.
''We are moving forward quickly to develop simple and easy to perform tests using this technology
for laboratories, hospitals and physicians' offices,'' said Zackary Irani, Biomerica Chief Executive
Officer. Biomerica was the first company in the world to develop a commercial laboratory blood test
to detect the presence of antibodies to H. pylori.
''We are developing the first test that will allow physicians to specifically identify high risk individuals
who require immediate treatment. The test will require only a blood sample and can be performed at
almost any clinical laboratory or physicians' office,'' Irani said.
H. pylori infection has been called the world's most prevalent disease, affecting as much as 70
percent of the world's population and one in three Americans.
Biomerica (Nasdaq: BMRA - news) is a global medical company devoted to developing,
manufacturing and marketing advanced medical diagnostics products for the early detection of
diseases. These products are used in hospitals, physicians' offices and in the home for self-testing. |
